Department of Gastric and Colorectal Surgery, General Surgery Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, Jilin, 130021, P.R. China.
BMC Cancer. 2022 Oct 5;22(1):1043. doi: 10.1186/s12885-022-10124-2.
Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and non-destructive technique for the study of cancers.
A total of 150 tissue samples from 25 rectal cancer patients were analyzed by liquid chromatography-mass spectrometry (LC-MS), and 6 tissue samples were collected from each patient (group 1: tumor; group 2: 0.5 cm from tumor; group 3:1 cm from tumor; group 4:2 cm from tumor; group 5:3 cm from tumor and group 6:5 cm from tumor). The differential metabolites of tumor tissues and 5 cm from the tumor (normal tissues) were first selected. The differential metabolites between tumor tissues and normal tissues were regrouped by hierarchical clustering analysis, and further selected by discriminant analysis according to the regrouping of clustering results. The potential safe margin of clinical T(cT)1,cT2 stage rectal cancer and cT3,cT4 stage rectal cancer at the metabolomic level was further identified by observing the changes in the level of differential metabolites within the samples from group 1 to group 6.
We found 22 specific metabolites to distinguish tumor tissue and normal tissue. The most significant changes in metabolite levels were observed at 0.5 cm (cT1, cT2) and 2.0 cm (cT3, cT4) from the tumor, while the changes in the tissues afterwards showed a stable trend.
There are differential metabolites between tumor tissues and normal tissues in rectal cancer. Based on our limited sample size, the safe distal incision margin for rectal cancer surgery in metabolites may be 0.5 cm in patients with cT1 and cT2 stage rectal cancer and 2.0 cm in patients with cT3 and cT4 stage rectal cancer.
直肠癌是最致命的胃肠道恶性肿瘤之一。代谢组学已逐渐发展成为一种研究癌症的便捷、廉价和无损技术。
采用液相色谱-质谱联用（LC-MS）对 25 例直肠癌患者的 150 个组织样本进行分析，每个患者采集 6 个组织样本（第 1 组：肿瘤；第 2 组：肿瘤 0.5cm 处；第 3 组：肿瘤 1cm 处；第 4 组：肿瘤 2cm 处；第 5 组：肿瘤 3cm 处；第 6 组：肿瘤 5cm 处）。首先选择肿瘤组织和距肿瘤 5cm 处（正常组织）的差异代谢物。根据聚类结果的重新分组，对肿瘤组织和正常组织的差异代谢物进行层次聚类分析重新分组，然后通过判别分析进一步选择。通过观察第 1 组至第 6 组样本中差异代谢物水平的变化，进一步确定在代谢组学水平上临床 T(cT)1、cT2 期直肠癌和 cT3、cT4 期直肠癌的潜在安全切缘。
我们发现了 22 种特定的代谢物来区分肿瘤组织和正常组织。在距离肿瘤 0.5cm（cT1、cT2）和 2.0cm（cT3、cT4）处观察到代谢物水平的最大变化，而随后组织的变化呈稳定趋势。
直肠癌肿瘤组织和正常组织之间存在差异代谢物。基于我们有限的样本量，直肠癌手术代谢物的安全远端切缘可能为 cT1 和 cT2 期直肠癌患者 0.5cm，cT3 和 cT4 期直肠癌患者 2.0cm。
